"The new Pharmacokinetics Module is not only a faster and more efficient way to search pharmacokinetics data, it is the only place to find this level of comparative exposure information, great for modeling and comparing therapeutic windows earlier in the development process", said Philip MacLaughlin, Senior Product Manager at Elsevier. "This is a level of information that stands alone as a resource for Pharmacokinetics data, as it can save months of work."
With the Pharmacokinetics Module, R&D professionals can model therapeutic windows faster and more accurately than previously possible and discover which preclinical experimental data is predictive of human response, which is not, and why. Users will have the ability to filter comparative data sets for decision support according to a wide variety of fields and special designations, including drug name, species, disease state, food effects, concomitant drugs, route, and exposure parameter.
The PharmaPendium(TM) module is available exclusively to existing PharmaPendium(TM) customers. Purchase options include annual subscription or data purchase (with annual maintenance fee).
PharmaPendium(TM) (http://www.info.pharmapendium.com/), allows the user to make informed drug development decisions. It is a unique online resource that provides access via a single point to searchable and trusted drug information. It covers close to 4,000 approved drugs, with integrated preclinical, clinical and post-market safety data.
PharmaPendium(TM) is designed to meet the needs of preclinical safety
assessment teams, toxicologists, pharmacokineticists, safety pharmacologists,
regulatory affairs staff, pharmacoepidemiologists, clinical researchers, drug
|SOURCE Elsevier and Elsevier Properties SA|
Copyright©2010 PR Newswire.
All rights reserved